CA2662749C - Processes for the preparation of 1,2,4-oxadiazole benzoic acids - Google Patents

Processes for the preparation of 1,2,4-oxadiazole benzoic acids Download PDF

Info

Publication number
CA2662749C
CA2662749C CA2662749A CA2662749A CA2662749C CA 2662749 C CA2662749 C CA 2662749C CA 2662749 A CA2662749 A CA 2662749A CA 2662749 A CA2662749 A CA 2662749A CA 2662749 C CA2662749 C CA 2662749C
Authority
CA
Canada
Prior art keywords
substituted
steps
butanol
tert
batch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2662749A
Other languages
English (en)
French (fr)
Other versions
CA2662749A1 (en
Inventor
Neil G. Almstead
Peter Seongwoo Hwang
Seemon Pines
Young-Choon Moon
James J. Takasugi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Priority to CA2842625A priority Critical patent/CA2842625C/en
Publication of CA2662749A1 publication Critical patent/CA2662749A1/en
Application granted granted Critical
Publication of CA2662749C publication Critical patent/CA2662749C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2662749A 2006-09-08 2007-09-06 Processes for the preparation of 1,2,4-oxadiazole benzoic acids Active CA2662749C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2842625A CA2842625C (en) 2006-09-08 2007-09-06 Processes for the preparation of 1,2,4-oxadiazole benzoic acids

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84359506P 2006-09-08 2006-09-08
US60/843,595 2006-09-08
PCT/US2007/019561 WO2008030570A1 (en) 2006-09-08 2007-09-06 Processes for the preparation of 1,2,4-oxadiazole benzoic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2842625A Division CA2842625C (en) 2006-09-08 2007-09-06 Processes for the preparation of 1,2,4-oxadiazole benzoic acids

Publications (2)

Publication Number Publication Date
CA2662749A1 CA2662749A1 (en) 2008-03-13
CA2662749C true CA2662749C (en) 2015-01-20

Family

ID=38935880

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2662749A Active CA2662749C (en) 2006-09-08 2007-09-06 Processes for the preparation of 1,2,4-oxadiazole benzoic acids
CA2842625A Active CA2842625C (en) 2006-09-08 2007-09-06 Processes for the preparation of 1,2,4-oxadiazole benzoic acids

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2842625A Active CA2842625C (en) 2006-09-08 2007-09-06 Processes for the preparation of 1,2,4-oxadiazole benzoic acids

Country Status (24)

Country Link
US (2) US7678922B2 (https=)
EP (1) EP2059513B1 (https=)
JP (2) JP5955494B2 (https=)
KR (1) KR101466368B1 (https=)
CN (1) CN101535284B (https=)
AR (3) AR062715A1 (https=)
AU (1) AU2007292915B2 (https=)
BR (1) BRPI0716996B8 (https=)
CA (2) CA2662749C (https=)
CL (1) CL2007002606A1 (https=)
DK (1) DK2059513T3 (https=)
ES (1) ES2404348T3 (https=)
IL (1) IL197445A (https=)
MX (1) MX2009002439A (https=)
MY (1) MY148598A (https=)
NZ (2) NZ575511A (https=)
PE (2) PE20120669A1 (https=)
PL (1) PL2059513T3 (https=)
PT (1) PT2059513E (https=)
RU (1) RU2495030C2 (https=)
TW (1) TWI482761B (https=)
UA (1) UA99265C2 (https=)
WO (1) WO2008030570A1 (https=)
ZA (1) ZA200901782B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
PL2402002T3 (pl) 2005-04-08 2018-11-30 Ptc Therapeutics, Inc. Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop
EP2387995A1 (en) 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
UA99265C2 (ru) * 2006-09-08 2012-08-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты)
US8101641B2 (en) 2006-09-25 2012-01-24 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof
NZ575795A (en) * 2006-09-25 2012-03-30 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
MX2009003909A (es) 2006-10-12 2009-05-25 Ptc Therapeutics Inc Métodos para dosificar un compuesto 1,2,4, - oxadiazol oralmente activo para el tratamiento de supresión de la mutación finalizadora.
CN101714009A (zh) * 2009-05-14 2010-05-26 翁印嵩 集成通用电话功能的计算机
ES2610362T3 (es) 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
EP2867230B1 (en) 2012-07-02 2020-02-12 Monsanto Technology LLC Process for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
TWI695717B (zh) 2014-03-06 2020-06-11 美商 Ptc 治療公司 １,２,４-二唑苯甲酸之鹽及醫藥組合物
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
CN108348527A (zh) 2015-10-30 2018-07-31 Ptc医疗公司 用于治疗癫痫的方法
TW201808922A (zh) 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
EP4473971A3 (en) 2019-04-10 2025-02-19 PTC Therapeutics, Inc. Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法
CN114920667B (zh) * 2022-06-30 2024-06-21 湖南大学 一种阿塔鲁伦酯的电化学制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801509A1 (de) * 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
DE3905242A1 (de) * 1989-02-21 1990-08-23 Basf Ag Verfahren zur herstellung von phenyloxdiazolylanilinen
NZ234760A (en) * 1989-08-18 1991-09-25 Sterling Drug Inc Antiviral oxazole compounds and compositions
DE4425794A1 (de) * 1994-07-21 1996-01-25 Basf Ag Nitrofarbstoffe
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
KR20040004705A (ko) 2001-06-08 2004-01-13 시토비아 인크. 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
MXPA05001592A (es) 2002-08-09 2005-05-05 Astrazeneca Ab Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
PL2402002T3 (pl) * 2005-04-08 2018-11-30 Ptc Therapeutics, Inc. Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop
UA99265C2 (ru) * 2006-09-08 2012-08-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты)

Also Published As

Publication number Publication date
AU2007292915B2 (en) 2012-07-26
AR107474A2 (es) 2018-05-02
BRPI0716996B1 (pt) 2021-02-09
PL2059513T3 (pl) 2013-06-28
RU2495030C2 (ru) 2013-10-10
CN101535284B (zh) 2014-12-10
BRPI0716996A2 (pt) 2013-10-08
US20080139818A1 (en) 2008-06-12
AU2007292915A1 (en) 2008-03-13
TW200823180A (en) 2008-06-01
KR20090054464A (ko) 2009-05-29
US20100063297A1 (en) 2010-03-11
IL197445A (en) 2014-01-30
MY148598A (en) 2013-05-15
CA2662749A1 (en) 2008-03-13
KR101466368B1 (ko) 2014-11-27
RU2009113019A (ru) 2010-10-20
MX2009002439A (es) 2009-03-27
NZ575511A (en) 2012-02-24
EP2059513B1 (en) 2013-01-23
WO2008030570A1 (en) 2008-03-13
JP5955494B2 (ja) 2016-07-20
CL2007002606A1 (es) 2008-04-18
PT2059513E (pt) 2013-04-30
ZA200901782B (en) 2010-06-30
EP2059513A1 (en) 2009-05-20
CN101535284A (zh) 2009-09-16
PE20080771A1 (es) 2008-06-13
CA2842625A1 (en) 2008-03-13
AR118922A2 (es) 2021-11-10
JP2010502715A (ja) 2010-01-28
UA99265C2 (ru) 2012-08-10
ES2404348T3 (es) 2013-05-27
US8367841B2 (en) 2013-02-05
BRPI0716996B8 (pt) 2021-05-25
AR062715A1 (es) 2008-11-26
IL197445A0 (en) 2009-12-24
DK2059513T3 (da) 2013-05-06
NZ598012A (en) 2013-08-30
US7678922B2 (en) 2010-03-16
TWI482761B (zh) 2015-05-01
PE20120669A1 (es) 2012-06-01
HK1134094A1 (en) 2010-04-16
CA2842625C (en) 2016-07-12
JP2014193896A (ja) 2014-10-09

Similar Documents

Publication Publication Date Title
CA2662749C (en) Processes for the preparation of 1,2,4-oxadiazole benzoic acids
US9630955B2 (en) Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
CA2716320C (en) Selective androgen receptor modulators
EP2336113A1 (en) CRTH2 Receptor Ligands for Medical Use
TW202530224A (zh) 製造巴洛沙韋瑪波西酯之方法
HK1134094B (en) Processes for the preparation of 1,2,4-oxadiazole benzoic acids
CN101228128A (zh) 一种用于制备取代苯基醚化合物和罗西格列酮的方法
EP2804607A2 (en) Synthesis of raltegravir
WO2002055454A2 (en) Process and product
WO2025037218A1 (en) Crystalline solvate of relugolix and a process for its preparation
CN1980664A (zh) 用于医学用途的crth2受体配体
CN102304125A (zh) 一种用于制备利奈唑胺的中间体
HK1107763B (en) Crth2 receptor ligands for medicinal uses

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250820

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250820